After medical studies at the Faculty of Medicine of Paris, Jacques Hugon completed an internship and an assistant professor ship in Neurology at the University Hospital of Limoges. He stayed as a visiting MD in Taiz hospital in Yemen for two years and was Research Associate for two years at the Albert Einstein College of Medicine in New York from 1984 to 1986. During this time he obtained a PhD thesis from the University of Paris on Guam disease, associating Parkinson's disease, dementia and ALS. He was then appointed in 1989, as tenure Professor in Neurology and Histology with the Faculty of Medicine in Limoges France. In 1998, he obtained a Chair Professorship with the Faculty of Medicine of the University of Hong Kong / Queen Mary Hospital and became Head of Department. On his return in 2003 he was appointed full professor at Poitiers University Hospital and worked at this hospital Memory Center. Since 2006 he is full professor and head of department with the Faculty of Medicine Paris Diderot and Lariboisière FW hospital and is responsible for the Memory Center of this hospital (CMRR North Paris Ile de France). He is also co-leader of an Inserm Unit on Translational Research in neurodegenerative diseases (INSERM UMR 942). His research currently focuses on the molecular mechanisms of neurodegeneration, on CSF and blood biomarkers in Alzheimer’s disease, new therapeutic targets and is involved in many clinical trials focusing on MCI, Alzheimer and other neurodegenerative diseases. He has co-authored more than 220 articles in peer-reviewed journal.
Professor Oscar López, Neurologist
Dr. Lopez is Professor of Neurology, Psychiatry, and Clinical and Translational Sciences, the Levidow-Pittsburgh Foundation Endowed Chair in Alzheimer’s disease and Dementia Disorders, and the Chief of the Cognitive and Behavioral Neurology Division. In addition, he is currently the Director of the Alzheimer’s Disease Research Center of Pittsburgh.
Dr. Lopez has conducted a large scale study in the clinical diagnosis of mild cognitive impairment (MCI), and was the Principal Investigator of the NIH-funded grant “Predictors of Alzheimer’s Disease in MCI; ancillary study of the Cardiovascular Health Study-Cognition Study (CHS-CS). The CHS-CS has conducted multiple clinical, laboratory and neuroimaging studies on risk factors for dementia in normal and MCI subjects. Specifically, Dr Lopez research has focused on the understanding of the interactions among multiple cerebral and systemic risk factors in relationship to the clinical expression of AD – either as dementia or MCI. The studies conducted at the CHS-CS suggested that vascular disease creates a vulnerability state to AD pathology, and modulates its clinical presentation. Consequently, it can accelerate the transition from normal to abnormal cognition, either MCI or AD, by attenuating the effect of physiological compensatory mechanisms. The CHS-CS, using perfusion MRI techniques, showed that there were decreases and increases in rCBF in specific brain regions in early AD and MCI (e.g., anterior cingulate gyrus, ventral striatum, hippocampus).
Dr. Lopez is currently conducting studies, as principal investigator and co-investigator, of the factors that modulate the transition from normal to MCI and to dementia in relationship to cerebral amyloid and tau deposition. These studies examine how cardiovascular and cerebrovascular factors create a vulnerability state for Alzheimer’s disease and neurodegeneration, and how they affect physiologically relevant compensatory mechanisms in the brain using MRI, FDG-PET, and Pittsburgh Compound B (PiB) and tau ligand technologies.
Pascual Sanchez-Juan, Neurologist
Scientific director of the Valdecilla Biobank and Head of Cognitive Impairment Unit of University Hospital Marqués de Valdecilla Santander (Spain). Master (MSc) (Netherlands Institute of Health Sciences) and PhD in Genetic Epidemiology at Erasmus MC (Rotterdam, The Netherlands).
Dr. Sánchez-Juan has participated in more than 100 publications indexed in Medline. The main scientific interests of Dr. Sánchez-Juan are neurodegenerative diseases, particularly prion diseases and Alzheimer's disease. His publications include first authorship in two genome-wide association studies on prion disease. He is also first or senior author of some pivotal highly cited articles in the field of prion diseases biomarkers, and he is the senior author of the current clinical diagnostic criteria for Creutzfeldt Jakob disease.
Aiden Flynn, Biostatistics
Aiden Flynn is a co-founder of Exploristics and has more than 20 years experience in drug discovery and clinical development. After seven years as a Lecturer at University College London, he has spent ten years at GlaxoSmithKline as a Director of statistical support for biomarker studies across research and development. Throughout his career, he has gained extensive experience in numerous therapeutic areas and in the application and utility of numerous study types, data types, analysis tools and methods. He has a PhD in Biophysics, MSc in Medical Physics and BSc in Applied Mathematics and Physics. He has more than 40 publications in peer reviewed journals and as an invited speaker at international conferences.
Ángel Sanz Granda, Health economics
MSc, PharmD, works as an independent health economics consultant since 2000 in several fields as cancer, cardiology, transplantation, diabetes, pain, psychiatry, rare diseases and respiratory. Angel has led the pharmacoeconomic analysis of several drugs, medical devices and diagnostic tests. Finally, he has published several scientific and divulgation papers and some books on health technology assessment.
Maurizio Suppo, Regulatory
Maurizio Suppo obtained his Ph.D. in molecular biology from the University of Turin (Italy) in 1985. Maurizio has more than 25 years of experience in the field of regulatory affairs and quality systems. He was the Director of the European Diagnostic Manufacturers Association (EDMA) and had a significant role in the development of the European IVD Directive 98/79/EC. His knowledge and experience in QA&RA go beyond the European borders. Before joining Qarad in July 2012, Maurizio has held the positions of Vice President of Regulatory Affairs and Quality Systems and of Standardization, Technology and Industry Affairs at Siemens Healthcare (Germany)
Guillermo Serrano, Fund raising
25 years experience in financial markets both in Europe and in the Americas. A graduate of the London School of Economics, his early years in the Spanish equities market with Hoare Govett and Goldman Sachs served as springboard to a number of Emerging Markets roles. He joined Barings in Latin America in 1994 to becoming Head of Infrastructure Research with Santander, Head of Latin American research with Dresdner Kleinwort Benson and Head of Latin America Institutional Equity Sales with BBVA.
Since 2005, Guillermo has developed an expertise in emerging technologies in the London market and has been instrumental in the success of numerous transactions such as Ceramic Fuel Cells, TMO Renewables, MDx Health, Ilika, ITM Power, Biotie, Vernalis, Futura Medical, Carmat, Silence Therapeutics, Sygnis/X-Pol and InterCell.
Jörg Endermann, IVD-Consultant
Jörg is a consultant dedicated to IVD with 28 years’ experience exclusively in the IVD industry. He has a degree as Engineer for biomedical technique. During his career, he has gained intensive experience in Marketing, Service and R&D. Jörg was 7 years’ site leader and Vice President Engineering at Siemens Healthcare and is an expert in the area of coagulation, hematology, specialty testing and IDD. His focus are design reviews on cost reduction, serviceability and manufacturability as well as project management.
Jörg founded 2015 his own company and works as independent consultant and coach.